<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>AIMS: Neuropilin-2 is a coreceptor for vascular endothelial growth factor family members </plain></SENT>
<SENT sid="1" pm="."><plain>Blockade of neuropilin-2 is able to suppress lymphogenous <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastasis</z:e> in preclinical models </plain></SENT>
<SENT sid="2" pm="."><plain>The aim of this study was to validate a protocol for the evaluation of neuropilin-2 protein expression in situ, by comparison with in-situ hybridization, western blotting, and <z:chebi fb="2" ids="33699">mRNA</z:chebi> expression levels </plain></SENT>
<SENT sid="3" pm="."><plain>METHODS AND RESULTS: Immunohistochemistry was performed on <z:mpath ids='MPATH_458'>normal</z:mpath> human tissues, and whole sections for 79 primary non-small-cell <z:mp ids='MP_0008714'>lung carcinomas</z:mp>, 65 primary <z:hpo ids='HP_0003002'>breast carcinomas</z:hpo>, 79 primary <z:e sem="disease" ids="C1527249" disease_type="Neoplastic Process" abbrv="">colorectal cancers</z:e>, and 52 metastases </plain></SENT>
<SENT sid="4" pm="."><plain>Neuropilin-2 expression was observed in lymphatic and blood vessels from <z:hpo ids='HP_0000001'>all</z:hpo> <z:mpath ids='MPATH_458'>normal</z:mpath> and malignant tissues examined </plain></SENT>
<SENT sid="5" pm="."><plain>In addition, 32% of primary non-small-cell <z:mp ids='MP_0008714'>lung carcinomas</z:mp>, 15% of primary <z:hpo ids='HP_0003002'>breast carcinomas</z:hpo> and 22% of primary <z:e sem="disease" ids="C1527249" disease_type="Neoplastic Process" abbrv="">colorectal cancers</z:e> showed <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e> cell expression </plain></SENT>
<SENT sid="6" pm="."><plain>Fifty-five primary and nine secondary <z:hpo ids='HP_0002861'>malignant melanomas</z:hpo> were also examined for neuropilin-2 expression by in-situ hybridization </plain></SENT>
<SENT sid="7" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> showed vascular expression, and 85% of primary <z:hpo ids='HP_0002861'>malignant melanomas</z:hpo> showed <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e> cell expression </plain></SENT>
<SENT sid="8" pm="."><plain>CONCLUSIONS: In the majority of lung, breast and <z:e sem="disease" ids="C1527249" disease_type="Neoplastic Process" abbrv="">colorectal cancers</z:e>, the effects of anti-neuropilin-2 are likely to be restricted to the vasculature </plain></SENT>
<SENT sid="9" pm="."><plain>These results will assist in pharmacokinetic evaluations, tolerability assessments and the choice of setting to evaluate the activity of anti-neuropilin-2 therapies </plain></SENT>
</text></document>